期刊
JOURNAL OF CLINICAL PHARMACOLOGY
卷 51, 期 5, 页码 672-678出版社
WILEY
DOI: 10.1177/0091270010372626
关键词
5-aminofluorescein; human serum albumin; pharmacokinetics; brain neoplasms
In a phase I/II study, the new fluorescence marker 5-aminofluorescein covalently bound to human serum albumin (AFL-HSA) was intravenously administered to 10 patients with brain tumor 1 to 4 days before surgery, and AFL-HSA kinetics were determined to assess the optimum timing of dye administration. AFL-HSA was determined in serum and brain tissue by size exclusion chromatography with fluorescence detection. AFL-HSA disposition was quite similar to albumin kinetics with small volumes of distribution (volume of central compartment [V-c] = 2.4 L; volume of distribution [Vd(beta)] = 6.8 L; volume at steady state [V-ss] = 5.9 L), a low clearance (mean Cl = 16.85 mL/h), and a long elimination half-life (mean T-1/2 beta = 307 hours). Predicted peak concentrations in the peripheral compartment occurred at 80.9 hours, the time point of optimal fluorescence intensity observed in brain tumors during surgery.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据